PBF 509Alternative Names: PBF-509
Latest Information Update: 02 May 2016
At a glance
- Originator Palobiofarma
- Class Antiparkinsonians
- Mechanism of Action Adenosine A2A receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Lung cancer; Non-small cell lung cancer
- No development reported Attention-deficit hyperactivity disorder; Parkinson's disease